Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and Non-human Primates

Shuyu Shou1, Menghui Liu1, Yang Yang1, Ning Kang1, Yingying Song1, Dan Tan1, Nannan Liu1, Feifei Wang1, Jing Liu1 and Youhua Xie1,2*

1 Key Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Fudan University, Shanghai, China,
2 Children’s Hospital, Fudan University, Shanghai, China

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus causing acute respiratory tract infection in humans. The virus has the characteristics of rapid transmission, long incubation period and strong pathogenicity, and has spread all over the world. Therefore, it is of great significance to select appropriate animal models for antiviral drug development and therapeutic effect evaluation. Here, we review and compare the current animal models of SARS-CoV-2.

Keywords: COVID-19, SARS-CoV-2, ACE2 (angiotensin converting enzyme 2), animal model, pathogenesis

INTRODUCTION

In early December of 2019, a new coronavirus disease (coronavirus disease 2019, COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in Wuhan, China (Li et al., 2020). SARS coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2 all belong to the Betacoronavirus genus of Coronaviridae family and have typical coronavirus genome structure (Zhu et al., 2020). Bats are suspected to be the natural host of SARS-CoV-2 (Banerjee et al., 2019), while other animals such as turtles, pangolins, snakes, cats, rabbits, ferrets, and monkeys have been suggested as potential intermediate hosts (Liu et al., 2020a; Wu et al., 2020). The spike (S) protein on the surface of SARS-CoV-2 is responsible for binding angiotensin converting enzyme 2 (ACE2) receptor on target cell surface (Guo et al., 2020). The interaction between viruses and host-specific receptors is an important factor that limits species tropism of the pathogen (Douam et al., 2015).

Severe acute respiratory syndrome coronavirus 2 infection may cause mild to severe symptoms. Severe outcomes include acute respiratory distress syndrome (ARDS), sepsis, septic shock, multi-organ failure, and death (Harapan et al., 2020). According to one survey, 80.9% infections were mild, 4.7% eventually developed critical symptoms, and the overall case fatality rate was 2.3% (Zhang, 2020) which is lower than MERS (34.4%) and SARS (9.5%) (Munster et al., 2020b). However, some patients (especially elderly patients with diabetes or coronary heart disease) can deteriorate in a short period of time and rapidly progress to multi-organ failure or death (Chen N. et al., 2020; Zhou F. et al., 2020). Other conditions associated with high mortality in adults include hypertension and other preexisting respiratory diseases (Williamson et al., 2020). Similar to SARS and MERS, fast deterioration in COVID-19 patients has been linked to the development of cytokine storm (Huang et al., 2005; Zhou et al., 2014). Serum levels of pro-inflammatory cytokines,
such as interleukin-6 (IL-6), IL-1β, IL-2, IL-8, IL-17, granulocyte-colony stimulating factor (G-CSF), monocyte chemotactic protein-1 (MCP-1), interferon-γ-inducible protein-10 (IP-10), and interferon (IFN), are upregulated in most patients with severe symptoms (Huang et al., 2020; Tan et al., 2020) as a result of excessive immune response to SARS-CoV-2 infection (Hu et al., 2020). Besides, it has been observed that most severe cases have lymphopenia, displaying a sharp decrease in the number of CD4+ T cells, CD8+ T cells, B cells, and natural killer cells. Total leukocyte number was not remarkably changed in such patients, but neutrophils were increased (Huang et al., 2020; Tan et al., 2020), and the increase in neutrophil-to-lymphocyte ratio (NLR) has been associated with disease severity and poor clinical outcome (Cao, 2020). Such anomalies in cell counts and NLR will eventually disappear in convalescent patients (Zheng et al., 2020).

Animal models are valuable tools for elucidating the pathogenesis of SARS-CoV-2 and evaluating antiviral therapeutics and vaccines. We searched the literature for currently used COVID-19 animal models. This review attempts to summarize progresses made since the discovery of SARS-CoV-2 in the development and application of relevant animal models, and discusses each model’s strength and weakness (Table 2). Details about each animal model are listed in Table 1, including gender, age, inoculation, replication, pathology, immune response, and clinical signs.

CHINESE TREE SHREW

Chinese tree shrew (Tupaia belangeri chinensis), a squirrel-like and rat-sized mammal, is genetically close to primates (Fan et al., 2013). As emerging experimental animal, tree shrews have the advantages of small size, low feeding cost, and short reproductive cycle, and have been used as effective experimental animals to replace primates in biomedical research and drug safety testing, especially for research targeting hepatitis C and B viruses (Yan et al., 1996; Feng et al., 2017).

Two teams have conducted SARS-CoV-2 infection of tree shrews. In one study, after nasal inoculation, tree shrews displayed no clinical symptom except for an increase in body temperature, and SARS-CoV-2 RNA became detectable in nasal, throat, and anal swabs, and one serum sample. Highest virus shedding (copy number 10^5.52/ml) was recorded with a young tree shrew’s nasal swab at 6 days post inoculation (dpi) and the highest viral load is 10^9.08/ml obtained using pancreas of one adult tree shrew dissected at 14 dpi (Zhao et al., 2020). In contrast, Xu L. et al. (2020) failed to detect SARS-CoV-2 RNA in throat and anal swabs. In addition, lung was the main site for viral replication, followed by the digestive tissues and heart (Table 1; Zhao et al., 2020). Sections of lung tissues showed local mild lesions, including thickened alveolar septa and interstitial hemorrhage, in both studies. Zhao et al. (2020) also found some scant histopathological changes in brain, heart, liver, trachea, pancreas, etc. (Table 1). Moreover, laboratory examination found that serum albumin decreased after infection, while blood urea nitrogen and alanine aminotransferase increased, similar to the impaired liver and renal function observed during COVID-19 progression (Ronco et al., 2020; Xu L. et al., 2020; Zhang C. et al., 2020). It appears that SARS-CoV-2 only achieves limited virus replication and shedding, as well as insignificant pathogenesis, in tree shrews.

HAMSTER

Hamsters are widely used in the research of respiratory viruses (Schaecher et al., 2008; Iwatsuki-Horimoto et al., 2018). Hamster ACE2 binds tightly to the SARS-CoV-2 S protein and mediates its entry (Liu et al., 2021). Therefore, hamsters are a potential infection model for studying the pathogenesis of SARS-CoV-2 infections.

Syrian Hamsters (Mesocricetus auratus)

Syrian hamsters started developing rapid breathing, lethargy, ruffled fur, and weight loss at 2 dpi of SARS-CoV-2. The mean viral loads in the nasal turbinate, trachea, and lung were consistently the highest among all tested tissues (Table 1; Chan et al., 2020). Sia et al. (2020) detected SARS-CoV-2 replication in the duodenum but observed no obvious structural damage or inflammatory infiltration, which is similar to virus replication in the epithelial cells of the terminal ileum and colon of COVID-19 patients.

After infection, Syrian hamsters showed similar pathological manifestations as human COVID-19 pneumonia. Lung tissue displayed focal diffuse alveolar destruction, hyaline membrane formation, and mononuclear cell infiltration (Table 1; Chan et al., 2020). In addition, neutrophil extracellular traps, an important pathogenetic trigger in severe COVID-19 patients (Middleton et al., 2020), was observed in lungs of infected Syrian hamsters (Becker et al., 2021). Computed tomography (CT) detected patchy ground glass opacity with regions of lung consolidation at 2 dpi, and the most severe lung changes occurred at 7–8 dpi (Imai et al., 2020).

Severe acute respiratory syndrome coronavirus 2 infection could cause different degrees of multiple organs lesions in Syrian hamster, including spleen, lymph nodes, kidney, adrenal gland, ovary, etc. Among them, the adrenal gland showed focal to multifocal inflammation (Song et al., 2020). Splenic atrophy and myocardial degeneration could also be observed (Chan et al., 2020), which may be related to the occasional reports of heart failure and lymphopenia in human patients (Chen N. et al., 2020; Huang et al., 2020).

A study found that high-dose intranasal inoculation of SARS-CoV-2 (5 × 10^5 TCID50) in hamsters resulted in severe infection, whose primary manifestation was high levels of virus replication, severe extensive pneumonia, and partial mortality (Tostanoski et al., 2020). The high-dose hamster model recapitulates severe COVID-19 and might help to study the pathogenesis of serious clinical disease and to test antiviral agents. Disrupting of adaptive immunity is also a strategy for developing severe disease models. Cyclophosphamide-treated and RAG2 knockout (KO) hamsters infected with low doses of virus developed more severe and prolonged disease (Brocato et al., 2020). Low-dose virus-infected...
TABLE 1 | Experimental animal models for SARS-CoV-2.

| Animal | Gender | Age | Inoculation | Replication | Immune response | Clinical signs | Pathology | Lethality | Animal- \( \text{animal} \) trans \( \text{mission} \) | References |
|--------|--------|-----|-------------|-------------|-----------------|---------------|-----------|-----------|-----------------------------|-------------|
| Tree shrew | Male and female | Adult (1 year), aged (5–6 years) | \( 10^{2} \) TCID\( \text{50} \) | IN, OR, OC | RNA in lung conjunctive | NR | Lung radiographic abnormalities; pulmonary punctate hemorrhage | Non-lethal | NR | Xu L. et al., 2020 |
| Tree shrew | Male and female | Young (6–12 months), adult (2–4 years), old (5–7 years) | \( 10^{6} \) PFU | IN | Lung, digestive tissues, heart, pancreas, kidney | NR | Increased body temperature | Mild pulmonary abnormality; mild changes in some extrapulmonary organs | Non-lethal | NR | Zhao et al., 2020 |
| Syrian hamster | Male and female | 6–10 weeks | \( 10^{5} \) PFU | IN | Mainly in nasal turbinate, trachea, lung tissues, and intestine | Neutralizing antibody response, IFN-\( \gamma \), IL-4, IL-6, TNF-\( \alpha \), and IL-12p40 upregulated | Pneumonia, diffuse alveolar damage with extensive apoptosis in lung; mild changes in heart and spleen | Non-lethal | Yes | Chan et al., 2020 |
| Syrian hamster | Male | 4–5 weeks | \( 8 \times 10^{5} \) TCID\( \text{50} \) | IN | Lung, nasal turbinate, kidney, duodenum | Neutralizing antibody response | Pneumonia, mononuclear cell infiltration, nasal epithelial attenuation | Non-lethal | Yes | Sia et al., 2020 |
| Syrian hamster | Female | Young (1 month), adult (7–8 months) | \( 10^{5.5} \) or \( 10^{7} \) PFU | IN, OC | Trachea, lung, nasal turbinate, brain, or olfactory bulb | Neutralizing antibody response | Severe pneumonia; lung radiographic abnormalities | Non-lethal | Yes | Imai et al., 2020 |
| Syrian hamster | Male and female | 10–12 weeks | \( 5 \times 10^{5} \) or \( 5 \times 10^{4} \) TCID\( \text{50} \) | IN | Lung, nares, trachea, heart, gastrointestinal tract, brain, spleen, liver, kidney | Macrophages and CD3\(^{+} \) T lymphocytes infiltration in lung | Moderate to severe interstitial pneumonia | Lethal | NR | Tostanoski et al., 2020 |
| RAG2 KO Syrian hamster | Male and female | 11–12 weeks | \( 10^{4} \) PFU | IN | Lung, heart, liver, spleen, intestine, brain, kidney | Weight loss | Severe pneumonia | Lethal | NR | Brocato et al., 2020 |
| Roborovski dwarf hamster | Male and female | 5–7 weeks | \( 10^{5} \) or 5,000 PFU | IN | RNA in bucco-laryngeal swabs, serum sample; lung, jejunal, kidney | Decrease of body temperatures, weight loss, snuffling, dyspnea, and ruffled fur | Severe fulminant pneumonia | Lethal | NR | Trimpert et al., 2020 |
| Chinese hamster | Male and female | 5–7 weeks | \( 10^{5} \) PFU | IN | Lung, bucco-laryngeal swabs, blood samples | Weight loss, subtle drops in body temperatures | Bronchitis, pneumonia | Non-lethal | NR | Bertzbach et al., 2020 |
| BALB/c mice | Female | Aged (9 months), young (6 weeks) | \( 1.6 \times 10^{4} \) PFU | MASCp6 | Lung, trachea, heart, liver, spleen, brain, feces | IL-1\( \beta \), IL-6, and IL-5 upregulated | Mild to moderate interstitial pneumonia | Non-lethal | NR | Gu et al., 2020 |
| BALB/c or C57BL/6J mice | Female | Young (4–6 weeks), adult (8–9 weeks) | \( 10^{4.4} \) PFU HRB2B6M | IN | Respiratory tract | NR | Transient weight loss | Mild to moderate pneumonia | Non-lethal | NR | Wang et al., 2020 |

(Continued)
| Animal | Gender | Age | Dosage | Route | Inoculation | Replication | Immune response | Clinical signs | Pathology | Lethality | Animal-animal transmission | References |
|--------|--------|-----|--------|-------|------------|-------------|----------------|----------------|-----------|-----------|---------------------------|------------|
| BALB/c mice | Female | Adult (12 weeks), aged (1 year) | $10^5$ PFU SARS-CoV-2 | IN | Upper and lower airways | IL-3, TNF-α, and IL-1β upregulated in lung | No overt clinical signs | Impaired lung function; mild-to-moderate pneumonia; peribronchial lymphoid inflammation | Non-lethal | NR | Dinnon et al., 2020 |
| BALB/cAnNhsd mice | Female | Young (10 weeks), old (1 year) | $10^2$–$10^5$ PFU SARS-CoV-2 MA10 | IN | Upper and lower airways | IL-6, IL-1α, IL-1β, TNF-α, MCP-1, and IFN-γ upregulated | Weight loss | Severe pneumonia, edema, and diffuse alveolar damage | Lethal | NR | Leist et al., 2020 |
| C57BL/6J mice | Female | 10 weeks | $10^5$ PFU SARS-CoV-2 MA10 | IN | Respiratory tract | NR | Weight loss | Pneumonia | Non-lethal | NR | Leist et al., 2020 |
| BALB/c mice | Female | 4–6 weeks | $10^5$ PFU SARS-CoV-2 WBP-1 | IN | Lung, trachea, turbinates | IL-1β, TNF-α, MCP-1, and IL-10 upregulated in lung | Weight loss | Severe interstitial pneumonia | Lethal | NR | Huang et al., 2021 |
| hACE2 transgenic mice | Male and female | 6–11 months | $10^2$ TCID$_{50}$ SARS-CoV-2 HB-01 | IN | Lung tissues, RNA in intestine | Specific IgG antibodies against the S protein of SARS-CoV-2 at 21 dpi | Slight bristled fur, weight loss | Moderate interstitial pneumonia | Non-lethal | NR | Bao et al., 2020 |
| hACE2 mice | Female | Young (4.5 weeks), aged (30 weeks) | $4 \times 10^5$ PFU | IN | Respiratory tracts, brain | G-CSF, IFN-γ, IL-9, and MIP-1β upregulated in aged mice | Weight loss in aged mice | Intestinal pneumonia | Non-lethal | NR | Sun S.H. et al., 2020 |
| K18-hACE2 mice | Male and female | 6–9 weeks | $2.5 \times 10^4$ PFU 2019-nCoV/USA_WA1/2020 | IN | Lung, heart, spleen, kidney, brain | IFN-γ, IL-6, IL-11, CXCL10, etc., upregulated in lung, lymphopenia | Weight loss, exercise tolerance reduced, pulmonary function decreased | Severe interstitial pneumonia | Lethal | NR | Winkler et al., 2020 |
| K18-hACE2 mice | Male | 8–10 weeks | S1SP (400 µg/kg) | IT | None | IFN-γ, IL-6, MCP-1, TNF-α, and IFN-10 upregulated in lung | Weight loss | Alveolar inflammation and edema | Non-lethal | NR | Colunga Biancatelli et al., 2021 |
| hPFH4-hACE2 mice | Male and female | 8–10 weeks | $3 \times 10^4$ TCID$_{50}$ | IN | Lung, eye, heart, brain | Neutralization antibodies, lymphopenia | Weight loss, dyspnea, neurological symptoms | Severe interstitial pneumonia | Lethal | NR | Jiang et al., 2020 |
| hACE2-KI mice | Male and female | 8–10 weeks | $4 \times 10^5$ PFU | IT | NR | TNF-α, IL-1α, IL-1β, and MCP-1 upregulated | NR | Severe pneumonia, ARDS | Non-lethal | NR | Hong et al., 2021 |
| AdV-hACE2 mice | Male and female | 8–10 weeks | $10^5$ PFU 2019-nCoV/USA_WA1/2020 | IN, IV/IN | Lung, heart, liver, spleen, and brain | NR | Weight loss | Pneumonia | Non-lethal | NR | Hassan et al., 2020 |
| AdV-hACE2 mice | Male and female | 6–8 weeks | $10^5$ PFU 2019-nCoV/USA_WA1/2020, SARS-CoV-2/human/CHN/2020 | IN | Lung | Virus-specific CD4+ and CD8+ T cell responses peaked at 8 dpi, TNF, IFN-γ, IL-10, IL-15, IL-6, CCL2, CXCL10, and PDGFb upregulated in lung | Ruffled fur, hunching, difficulty breathing, weight loss | Vascular congestion and hemorrhage; alveolar edema; interstitial inflammatory cell infiltrates | Non-lethal | NR | Sun J. et al., 2020 |
| Animal         | Gender | Age            | Dosage        | Route | Inoculation                        | Replication                          | Immune response | Clinical signs                      | Pathology                                      | Lethality | Animal-animal transmission | References                          |
|---------------|--------|----------------|---------------|-------|-----------------------------------|---------------------------------------|-----------------|-------------------------------------|-----------------------------------------------|-----------|-----------------------------|---------------------------------------|
| VEEV-VRP-     | Female | 6–8 weeks      | $10^5$ PFU    | IN    | Lung                              | NLR increased                         | No obvious symptoms | Interstitial pneumonia              | Non-lethal                                    | NR        | NR                         | Zhang Y.N. et al., 2020               |
| HACE2 mice    |        |                |               |       |                                   |                                       |                  |                                     |                                |           |                            |                                      |
| Ferret        | Female | 3–4 months     | $10^5$ PFU    | IN    | Nasal turbinate, soft palate, tonsils | NR                                    | Fever, loss of appetite          | Mild peribronchitis, pneumonia             | Non-lethal                                    | NR        | NR                         | Shi et al., 2020                      |
| Ferret        | Male and female | 1–2 years | $10^5, 10^6$ TCID_{50} | IN | Nasal turbinate, trachea, lung, and intestine sections | NR                                    | Increased body temperature, weight loss, occasional coughs | Acute bronchiolitis                     | Non-lethal                                    | Yes       |                            | Kim et al., 2020                     |
| Ferret        | Female | 7 months       | $5 \times 10^2$, $5 \times 10^4$, or $5 \times 10^6$ PFU | IN | Upper respiratory tract          | Neutralizing response                | Reduced activity, ruffled fur | Mild bronchiolitis                     | Non-lethal                                    | NR        | NR                         | Ryan et al., 2021                     |
| Mink          | Male and female | 13 months | $5 \times 10^6$ PFU  | IN  | Ear, rectal, and nasal washes; RNA in nasal turbinate, soft palates, leum tonsils, all lung lobes, and submaxillary lymph nodes | NR                                    | Weight loss                           | Severe interstitial pneumonia; severe perivascularitis; moderate peribronchiolitis; nasal mucosa damage of the olfactory region | Non-lethal                                    | Yes       |                            | Shuai et al., 2020                   |
| Rhesus macaque| Male and female | 6–11 years | $7 \times 10^6$ TCID_{50} | IT  | Lung, trachea, and bronchus tract; RNA in oropharyngeal, nasal, and rectal swab | Leukocytes and neutrophils decreased, lymphocytes increased | Reduced appetite, weight loss | Lung radiographic abnormalities; interstitial pneumonia | Non-lethal                                    | NR        | NR                         | Shan et al., 2020                    |
| Rhesus macaque| Male and female | Adult      | $2.6 \times 10^6$ TCID_{50} | IN, IT, OC, OR | Nose, throat, rectal swabs; respiratory tract, lymphoid, and gastrointestinal tissues | Neutralizing response on 10 dpi; IL-1ra, IL-6, IL-10, IL-15, MCP-1, MIP-1β increased on 1 dpi; TGF-α decreased on 3 dpi | Reduced appetite, hunched posture, weight loss, pale appearance, and dehydration | Lung radiographic abnormalities; moderate interstitial pneumonia centered on terminal bronchioles | Non-lethal                                    | NR        | NR                         | Munster et al., 2020a                |
| Rhesus macaque| Male and female | Young (3–5 years), aged (15 years) | $10^6$ TCID_{50} | IT  | Nasal, throat and anastomoses | CDS$^+$ and CD4$^+$ T cells decline in young animals; lymphocytes decreased | Asthenia, weight loss | Typical interstitial pneumonia       | Non-lethal                                    | NR        | NR                         | Yu et al., 2020                      |
| African green monkey | Male and female | Adult | $4.6 \times 10^5$ PFU | IT and IN  | Respiratory tract, lymphoid tissue, heart, digestive tract, brain, eyes, urogenital tract | Neutralizing response                | Reduced appetite, elevated body temperature | Broncho-interstitial pneumonia            | Non-lethal                                    | NR        | NR                         | Woolsey et al., 2021                |

(Continued)
| Animal                  | Gender  | Age                  | Inoculation | Dosage          | Route               | Replication                                                                 | Immune response                                           | Clinical signs                                      | Pathology                                                                 | Lethality | Animal-animal transmission | References               |
|------------------------|---------|----------------------|-------------|-----------------|---------------------|-----------------------------------------------------------------------------|----------------------------------------------------------|--------------------------------------------------|--------------------------------------------------------------------------------|-----------|-----------------------------|--------------------------|
| African green monkey   | Male and female | About 16 years | 3.61 × 10^6 PFU | OR, IN, IT, IV, and OC | OR, IN, IT, IV, and OC | Viral RNA in buccal, nasal, pharyngeal, bronchial brush, and rectal swabs | IFN-γ, IL-6, IL-4/IL-13, IL-8, IL-10, and TNF-α upregulated | Reduced appetite, respiratory distress | Interstitial pneumonia, ARDS | Lethal | NR                          | Blair et al., 2021         |
| Cynomolgus macaque     | Male and female | Adult               | 4.75 × 10^6 PFU | IN, IT, OC   | IN, IT, OC   | RNA in nasal swabs, throat swabs, anal swabs, feces, blood, lung, trachea, bronchus, and spleen | Virus-specific antibodies; IL-10, IL-1a, IL-8, IL-15, and MCP-1 upregulated | Elevated body temperature, weight loss | Lung radiographic abnormalities; diffuse interstitial pneumonia; inflammation in liver and heart; hyperplasia of mesenteric lymph nodes; mild infiltration of local inflammatory cells in kidney | Non-lethal | NR                          | Lu et al., 2020            |
| Cynomolgus macaque     | Female  | Young adult (4–5 years), aged adult (15–20 years) | 10^6 TCID<sub>50</sub> | IT, IN       | IT, IN       | RNA in nasal, throat, and rectal swabs; respiratory tract, ileum and tracheo-bronchial lymph nodes | Virus-specific antibodies | Serous nasal discharge in one aged animal | Pneumonia, diffuse alveolar damage, pulmonary edema | Non-lethal | NR                          | Rockx et al., 2020         |
| Common marmoset        | Male and female | Adult               | 10^6 PFU     | IN            | IN            | RNA in nasal, throat, and anal swabs, blood | Undetectable virus-specific antibodies in serum | Slightly elevated body temperature | Slight infiltration of inflammatory cells into the broken pulmonary septum; swollen hepatocytes; light hemorrhage observed in spleen | Non-lethal | NR                          | Lu et al., 2020            |

IN, intranasal; IT, intratracheal; IG, intragastric; OC, ocular; OR, oral; IV, intravenous; TCID<sub>50</sub>, 50% median tissue culture infectious dose; PFU, plaque forming units; FFU, focus forming unit; dpi, day post infection; NR, not reported; wk, week; mo, month; yr, year; IgM, immunoglobulin M; IgG, immunoglobulin G; IL, interleukin; TNF, tumor necrosis factor.
Hamsters infected with $10^5$ also proven to be a highly susceptible model of SARS-CoV-2. Roborovski dwarf hamster, the smallest hamster in the world, has been tested for SARS-CoV-2 infection (Bertzbach et al., 2020). Chinese hamsters are smaller than Syrian hamsters, and have been tested for SARS-CoV-2 infection (Bertzbach et al., 2020). Decreases in body weights post infection were significant and infected hamsters failed to regain lost weight by the end of the experiment at 14 dpi. Histopathology revealed pneumonia and alveolar damage similar to what has been observed in Syrian hamsters (Table 1; Bertzbach et al., 2020). However, the course of bronchitis and pneumonia described in Chinese hamsters was milder compared to Syrian hamsters, and pneumonia was more prolonged. Evident acute alveolar damage was present until 14 dpi with persistence of viral RNA (Bertzbach et al., 2020). Chinese hamsters are highly susceptible to diabetes, which may be used to establish COVID-19 model with preexisting diabetes (Gerritsen, 1982).

**Chinese Hamster (Cricetulus griseus)**

Chinese hamsters are smaller than Syrian hamsters, and have been tested for SARS-CoV-2 infection (Bertzbach et al., 2020). Decreases in body weights post infection were significant and infected hamsters failed to regain lost weight by the end of the experiment at 14 dpi. Histopathology revealed pneumonia and alveolar damage similar to what has been observed in Syrian hamsters (Table 1; Bertzbach et al., 2020). However, the course of bronchitis and pneumonia described in Chinese hamsters was milder compared to Syrian hamsters, and pneumonia was more prolonged. Evident acute alveolar damage was present until 14 dpi with persistence of viral RNA (Bertzbach et al., 2020). Chinese hamsters are highly susceptible to diabetes, which may be used to establish COVID-19 model with preexisting diabetes (Gerritsen, 1982).

Owing to the similarities to COVID-19 patients regarding clinical symptoms and histopathology, hamster-based models have become important tools for the study of SARS-CoV-2. Various drugs, antibodies, and vaccines are already being tested in Syrian hamsters and progresses have been reported (Kaptein et al., 2020; Kreye et al., 2020; Rogers et al., 2020; Kim et al., 2021; Ku et al., 2021).

**MOUSE**

Compared with other lab animals, mice offer many practical advantages including small sizes, multiple well-established strains, clear genetic background, highly available research tools, and ease of genetic manipulation. Due to the low affinity of mouse ACE2 (mACE2) for S protein of SARS-CoV-2, mice cannot be efficiently infected with wild type viruses (Wan et al., 2020). Two main approaches were adopted for circumventing the incompatibility of mACE2 with SARS-CoV-2 S protein: (1) the use of mouse-adapted SARS-CoV-2 strains; (2) expression of human ACE2 (hACE2) in mice. SARS coronavirus clinical isolates successively passaged in the respiratory tract of mice generated mouse-adapted strains MA15.
TABLE 2 | Advantages and disadvantages of SARS-CoV-2 animal models.

| Animal                        | Advantages                                                                 | Disadvantages                                                  |
|-------------------------------|-----------------------------------------------------------------------------|----------------------------------------------------------------|
| Chinese tree shrew            | Small size; low feeding cost; short reproductive cycle; evolutionarily close to primates. | No purebreds; limited virus replication and shedding; mild lung infection. |
| Syrian hamster                | Susceptibility to virus; lung damage similar to humans; viral transmission between individuals; the high challenge dose result in death. | Severe disease without typical manifestations of ARDS; short-lived infection kinetics. |
| Roborovski dwarf hamster      | Highly sensitive; rapid and consistent development of clinical signs; lethal outcome; less prone to aggressive behavior. | Not widely used; lack of relevant research tools. |
| Chinese hamster               | Pronounced clinical symptoms; small size; well-characterized genome.        | Prolonged pneumonia increasing time and cost. |
| Wild type mice (mouse-adapted virus strains) | Fast production at low-cost; age-dependent increase in disease severity; mild to lethal disease. | Insusceptible to wild type virus infection; virus replication limited to respiratory system. |
| hACE2 transgenic mice         | Susceptibility to wild type virus; mild to severe lung pathological changes. | Long production time and high cost; suboptimal SARS-CoV-2 replication. |
| AdV-hACE2 mice                | Fast production at low-cost.                                                 | hACE2 expressed non-systematically; mild bronchial inflammation associated with AdV; no extrapulmonary manifestations. |
| Ferret                        | Display symptoms of cough and fever, and transmission between animals.       | Virus replication only in the upper respiratory tract; mild lung pathological damage. |
| Mink                          | Severe to fatal infections; lung lesions highly similar to those in human patients. | Not widely used; aggressive animal. |
| African green monkey          | Robust viral replication; lethal outcome in aged; manifestations of ARDS.    | High cost; limited animal sources. |
| Rhesus macaque                | Phylogenetically close to human; symptoms similar to human infections; age-dependent increase in disease severity. | Non-lethal outcome; high cost. |
| Cynomologus macaques         | Phylogenetically close to human; asymptomatic infection in aged animals.      | Non-lethal outcome; high cost. |
| Common marmoset               | Phylogenetically close to human; smallest monkey allowing easy handling; breed well in captivity. | Relatively resistant to SARS-CoV-2 infection. |

FIGURE 1 | Phylogenetic analysis of ACE2 orthologs of 12 species and crucial ACE2 residues at the interface with the viral S protein. National Center for Biotechnology Information (NCBI) accession numbers for ACE2 are as follows: NP_001358344.1 (human), XP_008987241.1 (marmoset), XP_027288607.1 (Chinese hamster), NP_005593094 (cynomologus macaque), NP_001129188.1 (rhesus macaque), NP_005074266.1 (Syrian hamster), NP_001123985.1 (mouse), BA53380.1 (ferret), QPL0211.1 (mink), QPL07045.1 (Roborovski dwarf hamster), XP_006164754.1 (tree shrew), and AAV38782.1 (African green monkey) were analyzed and the phylogenetic tree was accomplished by MGEA-X (version 10.0.5). The 20 amino acid residues at the interface between human ACE2 and SARS-CoV-2 RBD are shown on the right (Shang et al., 2020). Each amino acid is identified by a different color.

and v2163, which caused lung damage and death in mice (Roberts et al., 2007; Day et al., 2009), Gu et al. (2020) used the same strategy and produced mouse-adapted SARS-CoV-2 strain MASCp6, which was infectious to mice and caused inflammatory responses and moderate pneumonia in both young and aged mice. The adaptive mutation of the strain, Asn501 to Tyr, at
the key site in the RBD of viral S protein increased the binding affinity of the protein to mACE2. Another mouse-adapted strain, HRB26M, only caused mild pathological changes in lung, same as MASCp6 (Wang et al., 2020). This method enables fast establishment of mouse model of infection to provide a large number of experimental animals that can be directly applied to the evaluation of therapeutic and vaccine candidates. However, wild type mice infected with mouse-adaptive virus strains may not necessarily reflect the situation of wild type SARS-CoV-2 infection (Table 2; Daniloski et al., 2020).

Dinnon et al. (2020) used reverse genetics to remodel the S and mACE2 binding interface and constructed a recombinant virus (SARS-CoV-2 MA) that utilizes mACE2 for entry. This recombinant strain replicated in the respiratory tract and was cleared within 4 dpi, causing mild to moderate pneumonia (Table 1). Leist et al. (2020) obtained a new mouse-adapted SARS-CoV-2 virus with increased pathogenicity, SARS-CoV-2 MA10, via serial passage of SARS-CoV-2 MA in the lungs of mice. MA10 infection caused acute lung injury and partial mortality in young BALB/c mice. The mortality rate of standard infection dose (10⁴ PFU) was 20% (Leist et al., 2020). Compared to mice with MA infection, more severely impaired lung function, significant changes in PenH (enhanced pause) and Rpef (the fraction of expiration time at which the peak occurs) at 2 dpi, was observed in MA10 infected adult mice. Besides, the levels of several pro-inflammatory cytokines (Table 1) in the lungs of aged adult mice with SARS-CoV-2 MA or MA10 infection, rather than in the serum, increased at 2 dpi. This more localized cytokine/chemokine responses may explain the longer time of virus clearance in aged mice than in young mice (Dinnon et al., 2020; Leist et al., 2020). The above two mouse-adapted strains exhibit an age-dependent disease severity in mice similar to COVID-19 patients (Table 2; Dinnon et al., 2020; Leist et al., 2020). In comparison to BALB/c mice, the infection of MA 10 led to less severe and non-lethal disease in C57BL/6J mice, revealing host genetic background could affect SARS-CoV-2 disease susceptibility (Leist et al., 2020). Recently, a mouse-adapted strain WBP-1 was found to produce lethal lung infections in mice. Q493K and Q498H substitutions in S protein of WBP-1 increased the binding affinity toward mACE2 (Huang et al., 2021).

In order to assess the anti-SARS-CoV-2 efficacy of remdesivir, which inhibits viral RNA-dependent RNA polymerase (RdRp), Pruijssers et al. (2020) constructed a chimeric mouse-adapted SARS-CoV variant, SARS/SARS2-RdRp, by replacing SARS-CoV RdRp with SARS-CoV-2 RdRp. This method is suitable for evaluating drugs with known target.

Transgenic Mice

Various antiviral agents and vaccines have so far been evaluated in transgenic mouse models for COVID-19 (Liu et al., 2020b; Ma et al., 2020; Colunga Biancatelli et al., 2021). After intranasal inoculation with SARS-CoV-2, transgenic mice expressing hACE2 by the mACE2 promoter showed symptoms of girdling and weight loss, as well as virus replication in the lungs (Bao et al., 2020). Infected mice progressed to moderate interstitial pneumonia with diffuse lesions at 5 dpi, and the pneumonia became mild with focal lesion areas at 7 dpi, while other organs displayed no obvious lesions (Table 1). In addition, a large number of macrophages and CD3+ T lymphocytes were found in the alveolar interstitium of hACE2 mice, and their numbers gradually increased with the course of infection (Bao et al., 2020). Another stable mouse model was generated, replacing the endogenous mACE2 with hACE2, by using CRISPR/Cas9 knockin (KI) technology (Sun S.H. et al., 2020). These hACE2 mice are highly susceptible to SARS-CoV-2 and demonstrate more robust virus replication in lung than hACE2 transgenic mice (Bao et al., 2020). Moreover, hACE2-KI mice (C57BL/6 background) with intratracheal inoculation of SARS-CoV-2 developed severe pneumonia with hyaline membranes-like changes, and can be used as an animal model for SARS-CoV-2-induced ARDS (Hong et al., 2021).

Two transgenic mouse models with hACE2 expression driven by the heterologous promoters showed lethal disease (jiang et al., 2020; Winkler et al., 2020). After intranasal inoculation of the virus, K18-hACE2 mice and HFH4-hACE2 mice (hACE2 expression under the control of human cytookeratin 18 promoter and HFH4/FOXJ1 promoter, respectively) lost weight and generated typical interstitial pneumonia. K18-hACE2 and HFH4-hACE2 mice with SARS-CoV-2 neuroinvasion would succumb to the infection. Severe pneumonia in K18-hACE2 mice was characterized by high levels of pro-inflammatory cytokines and chemokines (IFN-β, IL-6, IL-11, CXCL10, etc.) and substantial inflammatory cell infiltration in the lung. Lung consolidation caused by infection led to reduced exercise tolerance and impaired lung function in those mice (Winkler et al., 2020). HFH4-hACE2 mice with SARS-CoV-2 infection showed increased levels of creatine kinase, which may be related to edema and necrosis in some cardiomyocytes observed in heart tissue of mice (jiang et al., 2020).

Viral Vector-Mediated Delivery Systems

Human ACE2 expression in lung tissues of BALB/c mice was also achieved by intranasal administration of replication-defective adenoviruses (AdV) encoding hACE2 (AdV-hACE2). Five days later, mice were inoculated with SARS-CoV-2 and displayed weight loss, high virus replication in the lungs and pulmonary damage (Hassan et al., 2020). Lower levels of SARS-CoV-2 RNA could be detected in brain, liver, and spleen, but not in kidney, gastrointestinal tract, or serum (Table 1). The tissue distribution of virus infection may be related to the expression of hACE2 in different tissues in addition to the natural tropism of the virus (Hassan et al., 2020). Interestingly, Hassan et al. (2020) also found that there was no substantial difference between nasal inoculation alone and intranasal–intravenous combined routes in lung infection. It indicates that virus inoculation by a systemic route is not required in this animal model. Infected mice also showed a substantial increase in neutrophil infiltration in perivascular and alveolar locations after 8 dpi, and mice given anti-IFNAR1 monoclonal antibody showed more severe infection with an increase in macrophage infiltration at 8 dpi, similar to severe pneumonia in COVID-19 patients.
(Hassan et al., 2020). Those AdV-hACE2 mice treated with anti-Ifnar1 monoclonal antibody had relatively high levels of pro-inflammatory cytokines and chemokines such as IL-6, CCL2, CCL5, CXCL10, CXCL11, IFN-γ, and IFN-β in lung, indicating that inhibiting type I IFN signaling can aggravate inflammation and promote infection.

Sun J. et al. (2020) also used AdV-hACE2 for enabling SARS-CoV-2 infection of BALB/c and C57BL/6 mice, and found that infection in the two strains followed almost the same disease course. Infected BALB/c mice showed ruffled fur, hunching, and difficulty breathing after 2 dpi, and lost up to 20% of body weight at 4–6 dpi, while C57BL/6 mice lost about 10–15%. Histological examination showed that the most severe changes in the lungs were observed at 5 dpi (Sun J. et al., 2020). Compared with Adv-Empty transduced mice, expression of multiple genes were upregulated in lungs of AdV-ACE2 transduced mice infected with SARS-CoV-2, such as several cytokines and chemokines, including TNF, IFN-γ, IL-10, IL-15, IL-6, CCL2, CXCL10, and platelet-derived growth factor subunit B (PDGFβ), which was consistent with observations in COVID-19 patients (Table 1; Huang et al., 2020). The effects of several candidate vaccines and antiviral therapeutics (polynosinic-polycytidylic acid, remdesivir, 1B07 anti-S protein monoclonal antibody, etc.) have been evaluated in this animal model (Alsoussi et al., 2020; Hassan et al., 2020; Sun J. et al., 2020).

Venezuelan equine encephalitis replicon particles (VEEV-VRP) also can be used as an exogenous system for delivering hACE2 (Zhang Y.N. et al., 2020). After SARS-CoV-2 infection, this VEEV-VRP-hACE2 model developed interstitial pneumonia without obvious clinical symptoms, and the virus replication was limited to the lung (Table 2). A human neutralizing antibody CB6 showed strong protective effects against the virus in this model (Zhang Y.N. et al., 2020).

However, delivery of hACE2 with viral vector-mediated delivery systems can cause extra lesions in lung of mice, as mild bronchial inflammation induced by AdV and small areas of alveolar septal thickening induced by VEEV-VRP (Hassan et al., 2020; Zhang Y.N. et al., 2020). It remains a problem that the lung disease caused by viral vector may be confused with the pneumonia caused by SARS-CoV-2. The expression and tissue distribution of hACE2 is not systemic in this kind of models, and may vary among different mice. Consequently, hACE2 mouse model using viral vector-mediated delivery systems is not ideal for simulating systemic SARS-CoV-2 infection (Table 2).

Others

Severe acute respiratory syndrome coronavirus 2 must be handled in biosafety level three (BSL-3) facilities, which limits the development of urgently needed antiviral agents. Recombinant lentiviral viruses pseudotyped with SARS-CoV-2 S protein as the sole viral envelope protein has been demonstrated to be able to simulate SARS-CoV-2 virus infecting cells through S protein binding to hACE2 (Nie et al., 2020). Fan et al. (2018) reported successful infection of mice transgenic for MERS-CoV receptor using MERS-CoVs pseudovirus. hACE2 transgenic mice with pseudotyped SARS-CoV-2 infection have been applied in COVID-19 research (Cao et al., 2020; Bai et al., 2021). Such pseudoviruses can be handled in BSL-2 facilities and would greatly facilitate studies targeting both SARS-CoV-2 S protein in the context of infection, as well as other SARS-CoV-2 proteins in pathogenesis. Interestingly, recombinant subunit I of SARS-CoV-2 S protein (SISP), rather than the live virus, can induce alveolar and systemic inflammation in K18-hACE2 mice, while the intact S protein provokes minimal or no responses (Colunga Biancatelli et al., 2021). This protein-induced model provides another way to avoid the limitation of BSL-3 facilities for COVID-19.

Hassert et al. (2020) utilized an mRNA-based transfection system for transiently delivering hACE2 into type I interferon receptor 1 deficient (Ifnar1) mice to study the adaptive immune response to SARS-CoV-2. hACE2 mRNAs mainly target the lung and liver of mice, and a neutralizing antibody response was detected in those mice after SARS-CoV-2 infection (Hassert et al., 2020). The transfection efficiency of mRNA-ACE2 remains an issue in vivo according to the data presented (Hassert et al., 2020).

FERRET

Ferrets are naturally susceptible to SARS-CoV-2 infection. Infected ferrets showed mild clinical symptoms similar to human, including elevated body temperature, decreased activity, cough, and rhinorrhea (Kim et al., 2020; Park et al., 2020; Shi et al., 2020). The virus replicated efficiently in the upper respiratory tract of ferrets for up to 8 days (Shi et al., 2020). Viral RNA shedding was detectable up to 18 dpi in high-dose group (5 × 10⁶ PFU) (Ryan et al., 2021). RNA could be detected in ferret’s nasal wash, blood, nasal washes, urine, and fecal specimens, indicating diverse routes of shedding (Kim et al., 2020). Immunohistochemistry detected viral antigens in nasal turbinate, trachea, lung, and intestine (Kim et al., 2020), while histology analysis revealed severe lymphoplasmacytic periavascularitis, vasculitis, and mild peribronchitis in the lung (Table 1; Shi et al., 2020). Compared with pathological changes in COVID-19 patients with pulmonary edema and diffuse alveolar damage, virus-induced damage to ferret lungs is milder (Xu Z. et al., 2020). The mild lung pathology in the high-dose group ferrets was similar to the medium-dose group, but more extensive. No obvious lesions were observed in other tissue, except for multifocal inflammatory cell infiltration was observed in the portal areas of liver (Ryan et al., 2021). Ferrets are fully protected from acute lung pathology following re-challenge of the virus, which indicates naturally acquired immunity helps ferrets against reinfection (Patel et al., 2021; Ryan et al., 2021).

After direct contact with infected ferrets, all healthy naive ferrets showed moderate increases in body temperature and decreases in activity. Naive ferrets in indirect contact with infected ferrets through permeable partition did not show obvious symptoms, but some became positive for viral RNA in nasal washes and fecal specimens. It suggests that SARS-CoV-2 can be transmitted between ferrets through direct contact and airborne route, similar to transmission between humans (Kim et al., 2020; Richard et al., 2020). These results indicate that the
ferret model is excellent for studying SARS-CoV-2 transmission and mild infection (Table 2).

MINK

Severe acute respiratory syndrome coronavirus 2 outbreaks occurred in mink (Neovison vison) farms in the Netherlands, with infected minks showing signs of respiratory disease, including watery nasal discharge and even severe respiratory distress ending in death (Oreshkova et al., 2020). The virus was suspected to be transmitted from infected farm workers and then spread among the minks (Oreshkova et al., 2020). Highly diverse mink SARS-CoV-2 variants, including Y453F, F486L, and N501T, are found and spill over to humans (van Dorp et al., 2020; Oude Munnink et al., 2021). Escaped and wild minks infected with SARS-CoV-2 might become a virus reservoir, potentially constituting a pandemic threat (Koopmans, 2021).

After displaying clinical symptoms for 1 or 2 days, infected minks usually stopped eating and died on the next day (Molenaar et al., 2020). Histological examination revealed severe diffuse interstitial pneumonia with diffuse alveolar damage and formation of hyaline membranes in the lung (Molenaar et al., 2020; Oreshkova et al., 2020). Viral RNA could be detected in the conchae, lungs, liver, distal large intestine, throat swabs, and rectal swabs (Oreshkova et al., 2020) and SARS-CoV-2 isolated from mink (MT396266) was highly similar to circulating human isolates (Table 1; Sharun et al., 2020). Minks have transmitted SARS-CoV-2 to humans, and their high susceptibility to the virus suggest that they can easily become a natural reservoir (Enserink, 2020).

In laboratory settings, a SARS-CoV-2 strain isolated from human was used to infect minks intranasally (Shuai et al., 2020). Infection caused severe pathological injury similar to COVID-19 in the respiratory tracts of minks, as autopsy revealed severe interstitial pneumonia with extensive and diffuse consolidation, pulmonary thrombosis, nasal mucosa damage in the olfactory region, and nasal cavities filled with mucinous-purulent secretion. Immunohistochemical analysis of lung lobes showed the widespread distribution of SARS-CoV-2 antigen-positive cells; and high levels of virus replication were detected in turbinates, soft palate, lung lobes, and other tissues (Table 1; Shuai et al., 2020). The virus can be transmitted between minks via the air over more than 1 m distance (Kutter et al., 2021). Although minks infected in the laboratory did not die like infected farm minks, they lost 10–20% of body weight at around 8 dpi. In addition, a spike protein-based subunit vaccine candidate was evaluated using this mink model (Shuai et al., 2020).

NON-HUMAN PRIMATES

Rhesus Macaque (Macaca mulatta)

After inoculation with SARS-CoV-2 via a combination of intratracheal, intranasal, ocular, and oral routes, rhesus macaques showed changes in respiratory pattern (irregular, accelerated respiration), piloerection, and weight loss on 1 dpi (Table 1; Munster et al., 2020a). Pulmonary infiltrates were visible in lung radiographs of all animals, similar to what have been observed in patients with COVID-19. The symptoms could last 8–16 days and autopsy revealed pulmonary edema, pulmonary thrombosis, and interstitial pneumonia centered on terminal bronchioles (Munster et al., 2020a; Shan et al., 2020). Some rhesus monkeys generated neutralizing antibodies after infection, providing protection from secondary infection, which proved that humoral immunity produce a marked effect (Shan et al., 2020). Cytokine and chemokine levels in serum, such as IL-1ra, IL-6, IL-10, IL-15, MCP-1, macrophage inflammatory protein (MIP)-1β increased on 1 dpi, but minor decline was observed in transforming growth factor (TGF)-α on 3 dpi (Munster et al., 2020a). Virus loads were high in nasal swabs, throat swabs, and bronchoalveolar lavage fluids. Urogenital swabs remained negative in all animals, and only one rhesus monkey showed virus shedding from the rectum on 21 dpi. These observations indicate that the rhesus macaque infection model replicates moderate symptoms of COVID-19 patients. On the other hand, old macaques showed more severe diffuse interstitial pneumonia compared to young macaques and may thus be used for the study of more severe SARS-CoV-2 infection (Table 2; Yu et al., 2020).

Cynomolgus Macaque (Macaca fascicularis)

In one study, cynomolgus macaques inoculated with SARS-CoV-2 displayed increased body temperature and weight loss (Lu et al., 2020). In another similar study, however, the inoculated animals showed no overt clinical symptoms, except for a serious nasal discharge in one aged animal on 14 dpi (Rockx et al., 2020). This difference may be related to different methods and doses of virus inoculation. Both studies reported diffuse interstitial pneumonia. Besides, Lu et al. (2020) also found inflammation in liver and heart, and mild lesions in mesenteric lymph nodes and kidney (Table 1). By 14 dpi, there were virus-specific antibodies against the S and nucleocapsid proteins in the serum of all animals (Rockx et al., 2020). Viral shedding in upper respiratory tract of aged animals was prolonged to 21 dpi (Rockx et al., 2020). Compared with young adult animals, higher levels of viral RNA were detected in nasal swabs of aged animals. However, aged animals did not show more prominent lung infections or obvious clinical symptoms, which was different from rhesus macaques (Lu et al., 2020; Rockx et al., 2020).

African Green Monkey (Chlorocebus aethiops)

African green monkeys (AGMs) supported a higher level of viral replication than rhesus and cynomolgus macaques, for both SARS-CoV and SARS-CoV-2 (McAuliffe et al., 2004; Woolsey et al., 2021). After virus challenge, AGMs showed mild and various clinical symptoms, including decreased appetite, elevated body temperature, and even severe respiratory distress and death in two aged animals. Lung tissues developed extensive interstitial pneumonia with hyperemia and hemorrhage, and more severe
lesions with ARDS was observed in two of four aged animals (Blair et al., 2021; Woolsey et al., 2021). Aged AGMs may become a lethal model to mimic serious COVID-19 manifestations, including ARDS. Mild liver inflammation and chronic bilateral glomerulonephritis was noted in extrapulmonary organs of infected AGMs. The changes of systemic cytokines in AGMs following infection is consistent with COVID-19 patients: IFN-stimulated genes and IL-6 and IL-8 signaling upregulated (Woolsey et al., 2021). A study have evaluated the transmissibility and disease severity of SARS-CoV-2 B.1.1.7 variant in AGMs (Rosenke et al., 2021).

**Common Marmoset (Callithrix jacchus)**

Common marmoset, a New World monkey, has been used in research on a wide range of human diseases (Zühlke and Weinbauer, 2003; Adams et al., 2008). Compared with other non-human primates, it has smaller size, breeds well in captivity, and can be handled with ease. SARS-CoV-2 inoculated marmoset displayed no obvious clinical symptoms, with only one-third of animals showing slightly elevated body temperature (Table 2; Lu et al., 2020). Viral RNA could be detected in the peripheral blood from 2 to 8 dpi, and in nasal, throat, and anal swabs during 2 weeks post viral inoculation. Slight infiltration of inflammatory cells into pulmonary septum and mild lesions in liver and spleen were observed in histopathological examination (Table 1; Lu et al., 2020). Although no viral RNA was detected in tissue samples from the two tested marmosets, ultrastructural lesions in the lung and heart were observable under transmission electronic microscope (Lu et al., 2020). Additionally, virus-specific antibody was undetectable in the serum of marmosets during the experiment. These results indicate that, in contrast to cynomolgus and rhesus macaques, common marmoset is relatively resistant to SARS-CoV-2 infection and may not be a suitable animal model.

**COMPARISON OF ANIMAL MODELS**

**Susceptibility and Disease Severity**

ACE2 is a crucial factor that limits the sensitivity of the host to SARS-CoV-2. We select 11 species currently being used as SARS-CoV-2 animal models, and analyze the amino acid sequence of their ACE2 to construct a phylogenetic tree (Figure 1). The amino acid residues shown in Figure 1 can form hydrogen bonds or salt bridges with S protein to stabilize the binding (Shang et al., 2020; Liu et al., 2021). In primates, the 20 amino acid residues at the interface of human and the Old World monkeys, are exactly the same. But marmoset, a New World monkey, have lower residue conservation, which may explain its relatively resistance to SARS-CoV-2 infection. In addition, tree shrew are less susceptible to the virus (Liu et al., 2021).

The difference in ACE2 can partially explain the susceptibility of some species to viruses. Liu et al. (2021) found an interesting phenomenon: ACE2 of ferret and mink, which exhibit limited binding affinity with viral S1 protein, have the function of mediating the entry of SARS-CoV-2 in cell-level analysis. However, farm minks developed fatal infections, which constitutes a model of severe and potentially lethal infection of SARS-CoV-2 (Oreshkova et al., 2020). Therefore, the actual host–pathogen interaction is more complicated.

In summary, among the several animal models, three types of hamsters, ferret, mink, AGMs, rhesus, and cynomolgus macaque are highly susceptible to SARS-CoV-2, while marmoset, tree shrew, and wild-type mouse are relatively less susceptible.

Susceptible small animal models for COVID-19 are of great significance in evaluating antiviral agents and vaccines. Syrian hamster infected with high-dose virus and RAG2 KO hamsters developed lethal disease (Brocato et al., 2020; Tostanoski et al., 2020). Although wild-type mouse cannot be infected with SARS-CoV-2 in its natural state. Some mouse models (BALB/c mice infected with MA10, K18-hACE2, and HHF4-hACE2 mice) so far have reproduced severe respiratory disease that resemble pneumonia in severe COVID-19 in humans. In view of the time required for the development and production of transgenic mice, which usually takes from several months to years, approaches based on mouse-adapted or recombinant virus strains capable of infecting through mACE2, or expression of hACE2 in mouse lung cells are generally much quicker, and susceptible animals can be obtained in as fast as 2–3 weeks (Sun J. et al., 2020).

**Lung Pathology**

Typical pathological changes in the lung of COVID-19 patients include pulmonary edema with hyaline membrane formation, diffuse alveolar damage, type II pneumocyte hyperplasia, dilatation of capillary and occurrence of thrombosis, monocytes and macrophages within alveolar spaces, and interstitial mononuclear inflammatory infiltrates. Pulmonary fibrosis and consolidation in COVID-19 patients are usually milder compared to SARS patients, but mucus secretion tends to be more prominent in the former (Zhou B. et al., 2020). The most common patterns of COVID-19 pneumonia on chest CT were ground-glass opacity and bilateral patchy shadowing (Xu X. et al., 2020).

Mild pulmonary abnormality of tree shrew failed to recapitulates the typical characteristics of COVID-19. On the other hand, hamsters are promising models in this aspect. Syrian hamster infected with SARS-CoV-2 showed moderate to lethal broncho-interstitial pneumonia and bilateral ground-glass opacity on CT (Table 1), similar to the pneumonia characteristics of COVID-19 (Imai et al., 2020; Tostanoski et al., 2020). The lung pathology of Chinese hamster was roughly similar to that of Syrian hamster, but the pneumonia was milder and prolonged (Bertzbach et al., 2020). Notably, typical manifestations of ARDS, including severe acute diffuse alveolar damage and hyaline microthrombi, have been observed in infected Roborovski dwarf hamsters, providing the opportunity for studying SARS-CoV-2-related ARDS (Trimpert et al., 2020). Mild to severe interstitial pneumonia has been observed in different mouse models (Table 1). In contrast to K18-hACE2 transgenic mice, AdV-hACE2 mice develop lower titer viral replication and less obvious symptoms. Destroying the intact type I IFN response exacerbated lung pathology and clinical symptoms of AdV-hACE2 mice (Hassan et al., 2020; Rathnasinghe et al., 2020). Minks and ferrets, the closely related mustelids, displayed...
different patterns of viral replication (Shuai et al., 2020). SARS-CoV-2 replicated efficiently in both the upper and lower respiratory tract of minks, but only in the upper respiratory tract of ferrets (Shi et al., 2020; Shuai et al., 2020). Consequently, acute bronchiolitis in infected ferrets, is less similar to that of COVID-19 patients. Among all animals that have been used for modeling SARS-CoV-2 infection, three kinds of Old World monkeys are closest to human in terms of lung pathology, and common marmoset shows relatively milder lung damage.

Extrapulmonary Pathology
Some COVID-19 patients, especially those with severe infection, have extrapulmonary symptoms, such as kidney injury, cardiac complications, and neurologic manifestations (dizziness, impaired consciousness, taste impairment, smell impairment, etc.) (Chen N. et al., 2020; Mao et al., 2020; Zhou F. et al., 2020). Although the main target organ of SARS-CoV-2 is lung, the virus has a broad organotropism and can be detected in some extrapulmonary organs, including the kidneys, liver, heart, and brain, according to the result of autopsy (Puelles et al., 2020). Pathology results showed a few interstitial monocellular inflammatory infiltrates in heart tissue and severe acute tubular necrosis in kidney tissue (Zhou B. et al., 2020). In addition, lymphocytic panencephalitis, meningitis, ischemic damage, and microinfarcts were reported in postmortem brain of COVID-19 patients (von Weyhern et al., 2020; Song et al., 2021).

Although some animal models develop extrapulmonary manifestations of disease after infection as previously mentioned (Table 1), there is still a lack of an ideal model that can mimic the systemic response to SARS-CoV-2 infection in human.

Acute tubular necrosis, mild focal myocardial degeneration, and adrenal medulla atrophy could be observed in extrapulmonary tissues of Syrian hamsters (Song et al., 2020). Syrian hamster has been used in the study of myocardial pathology in COVID-19 (Chen S. et al., 2020). SARS-CoV-2 infection of cardiomyocytes, increased CCL2 expression and macrophage infiltration were reported in their heart tissues, which was confirmed in autopsy samples of COVID-19 patients. This study provides direct evidence that SARS-CoV-2 infects cardiomyocytes in vivo. Therefore, Syrian hamsters may be applied in pathological research of systemic SARS-CoV-2 infection.

In addition, SARS-CoV-2 is proved neutropotrop in some mouse models. After intranasal inoculation of the virus, 6-week-old K18-hACE2 mice showed some neurological symptoms, such as tremors and ataxic gait, and all animals died by 6 dpi (Kumari et al., 2021). Those mice also exhibited encephalitis features including production of cytokines and chemokines, leukocyte infiltration, and neuronal cell death (Kumari et al., 2021). SARS-CoV-2 could infect cells within the nasal turbinate, eye, and olfactory bulb, which related to smell impairment induced by infection of these cells in COVID-19 patients (Kumari et al., 2021). Besides, Song et al. (2021) observed the remodeling of brain vasculature in infected regions in this model. In conclusion, the severe neurological disease observed in K18-hACE2 mice is closely linked with the infection of nervous system in human patients, and this mouse model provide a valuable tool for studying the pathogenesis of infection in nervous system.

The primary manifestation of clinical disease in these hACE2 transgenic mouse models was encephalitis, rather than that of severe pneumonia has been reported in some hamster model, which limits them to systemic SARS-CoV-2 models (Tostanoski et al., 2020). Neuroinvasion also could be found in mice which expressed adeno-associated virus (AAV)-hACE2 expression in brain and then infected with SARS-CoV-2 intraventricularly. Those mice developed weight loss and death after infection (Song et al., 2021).

Host Immune Cellular Profile
The counts of white blood cells in the peripheral blood of COVID-19 patients are normal or decreased in the early stage of onset with the decrease in lymphocytes, and the progressive decrease in lymphocytes and increased inflammatory factors can be observed in severe patients (Huang et al., 2020).

According to the whole genome sequencing, the immune and nervous systems of tree shrew have high homology with those of human (Fan et al., 2013). In addition, some cytokines of tree shrew are similar to their human counterparts in terms of structure and function, such as IFN-λ3 and CXCL12 (Li et al., 2013; Chen et al., 2014). However, instead of lymphopenia often observed in human patients, tree shrews in the adult group increased white blood cells, lymphocytes, monocytes, and granulocytes but old group had a significant decrease in monocytes (Xu L. et al., 2020). The overall pattern of immune cellular profile is different from that in humans.

Shan et al. (2020) noticed leukocytes and neutrophils decreased, but lymphocytes increased in the blood of infected rhesus macaques. In another experiment, leukocytosis, neutrophilia, monocytosis, and lymphopenia were observed at 1 dpi, and then lymphocytes and monocytes returned to baseline, but the neutrophils continued to decline by 5 dpi (Munster et al., 2020a). In conclusion, rhesus macaques infected with SARS-CoV-2 showed neutropenia, lymphocytopenia, and increased NLR, similar to that observed in severe COVID-19 patients (Cao, 2020). And the number of T cells and monocytes in cynomolagus macaques peaked at 2 or 4 dpi, then gradually decreased and reached the lowest at 10 or 12 dpi, consistent with transient lymphocytopenia in rhesus macaques (Lu et al., 2020).

CONCLUSION
A variety of animal models for COVID-19 have been developed. Most animal models have mild to moderate infections. Minks, AGMs, certain mouse, and hamster models with critical infections can be applied to the pathogenesis study of severe COVID-19. Animals with low ACE2-binding affinity, such as mice, can be made susceptible to SARS-CoV-2 through engineering with expression of human hACE2 (transgenic technology or viral vector-mediated delivery systems) or by using adapted/recombinant virus strains.

The age-dependent increase in disease can be observed in some animal models. Researchers can consider age and other additional risk factors of COVID-19 to be incorporated into...
models to mimic human comorbidities. In addition, animal models administered with pseudovirus or viral proteins (SISP) which are not restricted by BSL-3 facilities can be established and used for research on COVID-19 pathogenesis.

**AUTHOR CONTRIBUTIONS**

SS and YX conceptualized the review. SS drafted the manuscript. YX, SS, ML, YY, NK, YS, DT, NL, FW, and JL revised the manuscript critically for important intellectual content and approved the version of the manuscript to be published.

**REFERENCES**

Adams, A. P., Aronson, J. F., Tardif, S. D., Patterson, J. L., Brasky, K. M., Geiger, R., et al. (2008). Common marmosets (Callithrix jacchus) as a nonhuman primate model to assess the virulence of eastern equine encephalitis virus strains. *J. Virol.* 82, 9035–9042. doi: 10.1128/jvi.00674-08

Alsoussi, W. B., Turner, J. S., Case, J. B., Zhao, H., Schmitz, A. J., Zhou, J. Q., et al. (2020). A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. *J. Immunol.* 205, 915–922. doi: 10.4049/jimmunol.2000583

Bai, L., Zhao, Y., Dong, J., Liang, S., Guo, M., Liu, X., et al. (2021). Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. *Cell Res.* 31, 395–403. doi: 10.1038/s41422-021-00473-1

Banerjee, A., Kulcsár, K., Misra, V., Frieman, M., and Mossman, K. (2019). Bats and Coronaviruses. *Viruses* 11v1100104. doi: 10.3390/v11001041

Bao, L., Deng, W., Huang, B., Gao, H., Liu, J., Ren, L., et al. (2020). The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. *Nature* 583, 830–833. doi: 10.1038/s41586-020-2312-y

Becker, K., Beythien, G., de Buhr, N., Stanelle-Bertram, S., Tuku, B., Kouassi, N. M., et al. (2021). Vasculitis and Neutrophil Extracellular Traps in Lungs of Golden Syrian Hamsters With SARS-CoV-2. *Front. Immunol.* 12:640842. doi: 10.3389/fimmu.2021.640842

Bertzbach, L. D., Vladimirova, D., Dietert, K., Abdelgawad, A., Gruber, A. D., Osterrieder, N., et al. (2020). SARS-CoV-2 infection of Chinese hamsters (Cricetulus griseus) reproduces COVID-19 pneumonia in a well-established small animal model. *Transbound Emerg. Dis.* 68, 1075–1079. doi: 10.1111/tbed.13837

Blair, R. V., Vaccari, M., Doyle-Meyers, L. A., Roy, C. J., Russell-Lodrigue, K., Fahlberg, M., et al. (2021). Acute Respiratory Distress in Aged, SARS-CoV-2-infected Syrian Hamsters. *J. Virol.* 95, 274–282. doi: 10.1161/j.ajpath.2020.10.016

Brocato, R. L., Principe, L. M., Kim, R. K., Zeng, X., Williams, J. A., Liu, Y., et al. (2020). Disruption of Adaptive Immunity Enhances Disease in SARS-CoV-2-infected Syrian Hamsters. *J. Virol.* 94:20. doi: 10.1128/jvi.01683-20

Cao, X. (2020). COVID-19: immunopathology and its implications for therapy. *Nat. Rev. Immunol.* 20, 269–270. doi: 10.1038/s41577-020-0308-3

Chen, S., Yang, L., Nilsson-Payant, B., Han, Y., Jaffré, F., Zhu, J., et al. (2020). SARS-CoV-2 Infected Cardiomyocytes Recruit Monocytes by Secreting CCL2. *Res. Sq.* [Preprint]. doi: 10.21203/rs.3.rs-9463/v1

Colunga Biancatelli, R., Sopolov, P., Sharlow, E. R., Lazo, J. S., Marik, P. E., and Catravas, J. D. (2021). The SARS-CoV-2 Spike Protein Subunit 1 induces COVID-19-like acute lung injury in K18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells. *Am. J. Physiol. Lung. Cell Mol. Physiol.* [Preprint]. doi: 10.1152/ajlphys.00232.2021

Danilowski, Z., Guo, X., and Sanjana, N. E. (2020). The D614G mutation in SARS-CoV-2 Spike increases transmission of multiple human cell types. *bioRxiv* [Preprint]. doi: 10.1101/2020.06.14.151357

Day, C. W., Baric, R., Cai, S. X., Frieman, M., Kumaki, Y., Morrey, J. D., et al. (2009). A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. *Virology* 395, 210–222. doi: 10.1016/j.virology.2009.09.023

Dinnon, K. H. III, Leist, S. R., Schäfer, A., Edwards, C. E., Martinez, D. R., Montgomery, S. A., et al. (2020). A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. *Nature* 586, 566–560. doi: 10.1038/s41586-020-2708-7

Douam, F., Gaska, J. M., Winer, B. Y., Ding, Q., von Schaewen, M., and Ploss, A. (2015). Genetic Dissection of the Host Tropism of Human-Tropic Pathogens. *Annu. Rev. Genet.* 49, 21–45. doi: 10.1146/annurev-genet-112014-054823

Ensrink, M. (2020). Coronavirus rips through Dutch mink farms, triggering culls. *Science* 368:1146. doi: 10.1126/science.368.6496.1169

Fan, C., Wu, X., Liu, Q., Li, Q., Liu, S., Lu, J., et al. (2018). A Human DPP4-Knockin Mouse's Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV. *Viruses* 10:v10090448. doi: 10.3390/v10090448

Fan, Y., Huang, Z. Y., Cao, C. C., Chen, C. S., Chen, Y. X., Fan, D. D., et al. (2013). Genome of the Chinese tree shrew. *Nat. Commun.* 4:4126. doi: 10.1038/ncomms4146

Feng, Y., Feng, Y. M., Lu, C., Han, Y., Liu, S., Sun, X., et al. (2017). Tree shrew, a potential animal model for hepatitis C, supports the infection and replication of HCV in vitro and in vivo. *J. Gen. Virol.* 98, 2069–2078. doi: 10.1099/jgv.0.008869

Gerritsen, G. C. (1982). The Chinese hamster as a model for the study of diabetes mellitus. *Diabetes* 31(Suppl. 1 Pt 2), 14–23. doi: 10.2337/dbah.31.1.s14

Gu, H., Chen, Q., Yang, G., He, L., Fan, H., Deng, Y. Q., et al. (2020). Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. *Science* 369, 1603–1607. doi: 10.1126/science.abc4730

Guo, Y. R., Cao, Q. D., Hong, Z. S., Tan, Y. Y., Chen, S. D., Jin, H. J., et al. (2020). The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. *Mil. Med. Res.* 7:11. doi: 10.1186/s40779-020-00240-0

Harapan, H., Itoh, N., Yufika, A., Winardi, W., Kearn, S., Te, H., et al. (2020). Coronavirus disease 2019 (COVID-19): A literature review. *J. Infect. Public Health* 13, 667–673. doi: 10.1016/j.jiph.2020.03.019

Hassan, A. O., Case, J. B., Winkler, E. S., Thackray, L. B., Kafai, N. M., Bay, A. L., et al. (2020). A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies. *Cell* 182, 744.e–753.e. doi: 10.1016/j.cell.2020.06.011

Hassett, M., Geerling, E., Stone, E. T., Steffen, T. L., Feldman, M. S., Dickson, A. L., et al. (2020). mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute
respiratory syndrome coronavirus 2. *PLoS Pathog.* 16:e1009163. doi: 10.1371/journal.ppat.1009163

Hong, W., Yang, J., Bi, Z., He, C., Lei, H., Yu, W., et al. (2021). A mouse model for SARS-CoV-2-induced acute respiratory distress syndrome. *Signal Transduct. Target Ther.* 6. doi: 10.1038/s41392-020-00451-w

Hou, Y. J., Chiba, S., Halfmann, P., Ebere, C., Kuroda, M., Dinnon, K. H. III, et al. (2020). SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. *Science* 370, 1464–1468. doi: 10.1126/science.abb4999

Hu, B., Huang, S., and Yin, L. (2020). The cytokine storm and COVID-19. *J. Med. Virol.* 93, 250–256. doi: 10.1002/jmv.26232

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 395, 497–506. doi: 10.1016/S0140-6736(20)30183-5

Huang, K. J., Su, I. J., Therom, M., Wu, Y. C., Lai, S. K., Li, C. C., et al. (2005). An interferon-gamma-related cytokine storm in SARS patients. *J. Med. Virol.* 75, 185–194. doi: 10.1002/jmv.20255

Huang, K., Zhang, Y., Hui, X., Zhao, Y., Gong, W., Wang, T., et al. (2021). Q493K and Q498H substitutions in Spike promote adaptation of SARS-CoV-2 in mice. *BioMedicine* 67:103381. doi: 10.1016/j.biemedi.2021.103381

Imai, M., Halfmann, P. J., Yamayoshi, S., Iwatsuki-Horimoto, K., Chiba, S., Watanabe, T., et al. (2021). Characterization of a new SARS-CoV-2 variant that emerged in Brazil. *Proc. Natl. Acad. Sci. U S A.* 118:2106535118. doi: 10.1073/pnas.2106535118

Imai, M., Iwatsuki-Horimoto, K., Hatta, M., Loebner, S., Halfmann, P. J., Nakajima, N., et al. (2020). Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. *Proc. Natl. Acad. Sci. U S A.* 117, 16587–16595. doi: 10.1073/pnas.2007997117

Iwatsuki-Horimoto, K., Nakajima, N., Ichiko, Y., Sakai-Takada, Y., Noda, T., Hasegawa, H., et al. (2018). Syrian Hamster as an Animal Model for the Study of Human Influenza Virus Infection. *J. Virol.* 92:17. doi: 10.1128/jvi.01693-17

Jiang, R. D., Liu, M. Q., Chen, Y., Shan, C., Zhou, Y. W., Shen, X. R., et al. (2020). An Interferon-lambda3 (IFN-λ3) and its cognate receptor subunits in tree shrews (Tupaia belangeri): genomic sequence retrieval, molecular identification and expression analysis. *PLoS One* 15:e0260048. doi: 10.1371/journal.pone.0260048

Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., et al. (2020). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N. Engl. J. Med.* 382, 1199–1207. doi: 10.1056/NEJMoai2001316

Liu, Y., Hu, G., Wang, Y., Ren, W., Zhao, X., Li, F., et al. (2021). Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2. *Proc. Natl. Acad. Sci. U S A.* 118, 2025373118. doi: 10.1073/pnas.2025373118

Liu, Z., Xiao, X., Wei, X., Li, J., Yang, J., Tan, H., et al. (2020a). Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. *J. Med. Virol.* 92, 595–601. doi: 10.1002/jmv.25726

Liu, Z., Xu, W., Xia, S., Gu, C., Wang, X., Wang, Q., et al. (2020b). RBDF-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. *Signal Transduct. Target Ther.* 5:282. doi: 10.1038/s41392-020-00402-5

Li, S., Zhao, Y., Yu, W., Yang, Y., Gao, J., Wang, J., et al. (2020). Comparison of SARS-CoV-2 infections among 3 species of non-human primates. *bioRxiv* [Preprint]. doi: 10.1101/2020.04.08.031807

Ma, X., Zou, F., Yu, F., Li, R., Yuan, Y., Zhang, Y., et al. (2020). Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses. *Immunity* 53, 1315–e1330. doi: 10.1016/j.immuni.2020.11.015

Mao, L., Jin, H., Wang, M., Hu, Y., Chen, S., He, Q., et al. (2020). Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurology.* 77, 683–690. doi: 10.1001/jamanetworkneurology.2020.1127

Maulife, J., Vogel, L., Roberts, A., Fähle, G., Fischer, S., Shieh, W. J., et al. (2004). Replication of SARS coronavirus administered into the respiratory tract of African green, rhesus and cynomolgus monkeys. *Virology* 330, 8–15. doi: 10.1016/j.virol.2004.09.030

Middleton, E. A., He, X. Y., Denorme, F., Campbell, R. A., Ng, D., Salvatore, S. P., et al. (2020). Neutrophil extracellular traps contribute to immunomodulation in COVID-19 acute respiratory distress syndrome. *Blood* 136, 1169–1179. doi: 10.1182/blood.2020007008

Molenaar, R. A., Vreman, S., Hakze-van, der Honing, R. W., Zwart, R., de Rond, J., et al. (2020). Clinical and Pathological Findings in SARS-CoV-2 Disease Outbreaks in Farmed Mink (Neovison vison). *Vet. Pathol.* 57, 653–657. doi: 10.1177/0300985820943535

Munster, V. J., Feldmann, F., Williamson, B. N., van Doremalen, N., Pérez-Pérez, L., Schulz, J., et al. (2020a). Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2. *bioRxiv* [Preprint]. doi: 10.1101/2020.03.21.001628

Munster, V. J., Koopmans, M., van Doremalen, N., van Riel, D., and de Wit, E. (2020b). A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment. *N. Engl. J. Med.* 382, 692–694. doi: 10.1056/NEJMmp200929

Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, L., et al. (2020). Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. *Emerg. Microbes Infect.* 9, 680–686. doi: 10.1002/emmb.20215.2020.1743767

Oreshkova, N., Molenaar, R. J., Vreman, S., Henders, F., Oude Munnink, R. B., Hakze-van, et al. (2020). SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020. *Euro. Surveill.* 25:2001005. doi: 10.2807/1560-7971.es.2020.25.23.2001005

Osterrieder, N., Bertzbauch, L. D., Dietert, K., Abdelgawad, A., Vladimirova, D., Kuneč, D., et al. (2020). Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters. *Viresus* 12:v20700779. doi: 10.1038/s12077-020-00779-0

Oude Munnink, B. B., Sikkema, R. S., Nieuwenhuijse, D. F., Molenaar, R. J., Munger, E., Molenkamp, R., et al. (2021). Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. *Science* 371, 172–177. doi: 10.1126/science.abe5901
Ronco, C., Reis, T., and Husain-Syed, F. (2020). Management of acute kidney injury in patients with COVID-19. *Lancet Respir. Med.* 8, 776–782. doi: 10.1016/s2213-2600(20)30076-x

Wang, P., Lau, S. Y., Deng, S., Chen, S., Pek, B. W., Zhang, J. A., et al. (2021). Pathogenesis and transmission of SARS-CoV-2 in hamsters. *Nature* 583, 834–838. doi: 10.1038/s41586-020-2342-5

Song, E., Zhang, C., Israelow, B., Lu-Culligan, A., Prado, A. V., Skrabiche, S., et al. (2021). Neuroinvasion of SARS-CoV-2 in human and mouse brain. *J. Exp. Med.* 218:20201315. doi: 10.1084/jem.20201315

Song, Z., Bao, L., Yu, P., Qi, F., Gong, S., Wang, J., et al. (2020). SARS-CoV-2 Causes a Systematically Multiple Organs Damages and Dissemination in Hamsters. *Front. Microbiol.* 11:618891. doi: 10.3389/fmicb.2020.618891

Sun, J., Zhuang, Z., Zheng, J., Li, K., Wong, R. L., Liu, D., et al. (2020). Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment. *Cell* 182, 734.e–743.e. doi: 10.1016/j.cell.2020.06.010

Sun, S. H., Chen, Q., Gu, H. J., Yang, G., Wang, Y. X., Huang, X. Y., et al. (2020). A Mouse Model of SARS-CoV-2 Infection and Pathogenesis. *Cell Host Microbe* 28, 124.e–133.e. doi: 10.1016/j.chom.2020.05.020

Tan, M., Liu, Y., Zhou, B., Deng, X., Li, F., Liang, K., et al. (2020). Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. *Immunology* 160, 261–268. doi: 10.1111/imm.13223

Tostanoski, L. H., Wegmann, F., Martinot, A. J., Loos, C., McMahan, K., Mercado, N. B., et al. (2020). Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. *Nat. Med.* 26, 1694–1700. doi: 10.1038/s41591-020-1070-6

Trimpert, J., Vladimirova, D., Dietert, K., Abdelgawad, A., Kunec, D., Dökel, S., et al. (2020). The Roborovski Dwarf Hamster Is A Highly Susceptible Model for a Rapid and Fatal Course of SARS-CoV-2 Infection. *Cell Rep.* 33:108488. doi: 10.1016/j.celrep.2021.108488

Wang, P., Les, S. Y., Deng, S., Chen, S., Pek, B. W., Zhang, J. A., et al. (2021). Broad host range of SARS-CoV-2 and the molecular basis for SARS-CoV-2 binding to cat ACE2. *Structure* 39, 1012–1015. doi: 10.1016/j.str.2021.06.010

Wang, Y., Yu, J., Hu, Y., Wang, H., Xiu, D., et al. (2021). Establishment of an African green monkey model for COVID-19. *Emerg. Microbes Infect.* 10.1080/22221751.2020.1838955

Wang, H., Li, L., Pan, X., Li, L., Cao, L., et al. (2020). Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. *Science* 369, 956–963. doi: 10.1126/science.abb7520

Ronco, C., Reis, T., and Husain-Syed, F. (2020). Management of acute kidney injury in patients with COVID-19. *Lancet Respir. Med.* 8, 738–742. doi: 10.1016/s2213-2600(20)30229-0

Rosenke, K., Feldmann, F., Okumura, A., Hansen, F., Tang-Huau, T., Meade-White, K., et al. (2021). UK B.1.1.7 variant exhibits increased respiratory replication and shedding in nonhuman primates. *bioRxiv* [Preprint]. doi: 10.1101/2021.04.18.448134

Ryan, K. A., Bewley, K. R., Fotheringham, S. A., Slack, G. S., Brown, P., Hall, Y., et al. (2021). Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity. *Nat. Commun.* 12:81. doi: 10.1038/s41467-020-20439-y

Schaecher, S. R., Stabenow, J., Oberle, C., Schriever, J., Buller, R. M., Sagartz, J. E., et al. (2008). An immunosuppressed Syrian golden hamster model for SARS-CoV infection. *Virology* 380, 312–312. doi: 10.1016/j.virol.2008.07.026

Shan, C., Yao, Y. F., Yang, X. L., Zhou, Y. W., Gao, G., Peng, Y., et al. (2020). Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques. *Cell Res.* 30, 670–677. doi: 10.1038/s41422-020-0364-z

Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Ahmara, H., et al. (2020). Structural basis of receptor recognition by SARS-CoV-2. *Nature* 581, 221–224. doi: 10.1038/s41586-020-2179-y

Sharan, K., Sirac, S., Malik, Y. S., Singh, R. K., and Dhama, K. (2020). How close is SARS-CoV-2 to canine and feline coronaviruses? *J. Small Anim. Pract.* 61, 523–526. doi: 10.1111/jass.13207

Shi, J., Wen, Z., Zhong, G., Yang, H., Wang, C., Huang, B., et al. (2020). Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-CoV-2. *Science* 368, 1014–1020. doi: 10.1126/science.abb7015

Shuai, L., Zhong, G., Yuan, Q., Wen, Z., Wang, C., He, X., et al. (2020). Replication, pathogenicity, and transmission of SARS-CoV-2 in minks. *Nat. Sci. Rev.* 2020:nwa2291. doi: 10.1038/nrrnwa2291
Shou et al. Advances in SARS-CoV-2 Animal Models

Yan, R. Q., Su, J. J., Huang, D. R., Gan, Y. C., Yang, C., and Huang, G. H. (1996). Human hepatitis B virus and hepatocellular carcinoma. I. Experimental infection of tree shrews with hepatitis B virus. J. Cancer Res. Clin. Oncol. 122, 283–288. doi: 10.1007/bf01261404

Yu, P., Qi, F., Xu, Y., Li, F., Liu, P., Liu, J., et al. (2020). Age-related rhesus macaque models of COVID-19. Anim. Model Exp. Med. 3, 91–97. doi: 10.1002/ame2.12108

Yuan, L., Zhu, H., Zhou, M., Ma, J., Chen, R., Chen, Y., et al. (2021). Gender associates with both susceptibility to infection and pathogenesis of SARS-CoV-2 in Syrian hamster. Signal Transduct. Target Ther. 6:136. doi: 10.1038/s41392-021-00552-0

Zhang, C., Shi, L., and Wang, F. S. (2020). Liver injury in COVID-19: management and challenges. Lancet Gastroenterol. Hepatol. 5, 428–430. doi: 10.1016/s2468-1253(20)30057-1

Zhang, Y. (2020). Vital Surveillances: The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. China CDC Weekly 2, 113–122. doi: 10.46234/ccdcw2020.032

Zheng, M., Gao, Y., Wang, G., Song, G., Liu, S., Sun, D., et al. (2020). Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol. Immunol. 17, 533–535. doi: 10.1038/s41423-020-0402-2

Zhou, B., Zhao, W., Feng, R., Zhang, X., Li, X., Zhou, Y., et al. (2020). The pathological autopsy of coronavirus disease 2019 (COVID-2019) in China: a review. Pathog. Dis. 78:ftaa026. doi: 10.1093/femspd/ftaa026

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Shou, Liu, Yang, Kang, Song, Tan, Liu, Wang, Liu and Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.